Table 2.
PTGS1 and PTGS2 polymorphism frequency by incident ischemic stroke or CHD case status
| Caucasian
|
African American
|
|||||
|---|---|---|---|---|---|---|
| Genotypea | Non-cases | Cases | P-value | Non-cases | Cases | P-value |
| Stroke | n=671b | n=151b | n=326b | n=119b | ||
| G-1006A (PTGS1) | ||||||
| G/G | 583 (89.4%) | 121 (81.8%) | 246 (76.9%) | 84 (73.0%) | ||
| G/A+A/A | 71 (10.6%) | 27 (18.2%) | 0.027 | 70 (23.1%) | 31 (27.0%) | 0.436 |
| R8W (PTGS1) | ||||||
| C/C | 571 (86.7%) | 131 (87.9%) | 308 (97.1%) | 112 (97.4%) | ||
| C/T+T/T | 85 (13.3%) | 18 (12.1%) | 0.694 | 8 (2.9%) | 3 (2.6%) | NA |
| P17L (PTGS1) | ||||||
| C/C | 564 (89.3%) | 123 (84.3%) | 229 (72.1%) | 81 (71.7%) | ||
| C/T+T/T | 69 (10.7%) | 23 (15.7%) | 0.125c | 90 (27.9%) | 32 (28.3%) | 0.758 |
| G230S (PTGS1) | ||||||
| G/G | 654 (100%) | 149 (100%) | 311 (98.8%) | 112 (97.4%) | ||
| G/A+A/A | 0 (0%) | 0 (0%) | NA | 3 (1.2%) | 3 (2.6%) | NA |
| L237M (PTGS1) | ||||||
| C/C | 604 (93.6%) | 143 (94.7%) | 312 (99.2%) | 114 (99.1%) | ||
| C/A+A/A | 43 (6.4%) | 8 (5.3%) | 0.613 | 3 (0.8%) | 1 (0.9%) | NA |
| G-765C (PTGS2) | ||||||
| G/G | 457 (70.7%) | 111 (74.5%) | 154 (50.6%) | 44 (38.6%) | ||
| G/C+C/C | 195 (29.3%) | 38 (25.5%) | 0.353 | 149 (49.4%) | 70 (61.4%) | 0.032 |
| V511A (PTGS2) | ||||||
| T/T | 635 (100%) | 149 (100%) | 290 (91.6%) | 104 (92.0%) | ||
| T/C+C/C | 0 (0%) | 0 (0%) | NA | 28 (8.4%) | 9 (8.0%) | 0.877 |
| CHD | n=626b | n=792b | n=315b | n=231b | ||
| G-1006A (PTGS1) | ||||||
| G/G | 542 (89.2%) | 666 (86.6%) | 234 (75.9%) | 168 (76.4%) | ||
| G/A+A/A | 68 (10.8%) | 103 (13.4%) | 0.164 | 72 (24.1%) | 52 (23.6%) | 0.906 |
| R8W (PTGS1) | ||||||
| C/C | 533 (86.7%) | 669 (86.6%) | 298 (97.0%) | 218 (98.2%) | ||
| C/T+T/T | 79 (13.3%) | 104 (13.5%) | 0.952 | 8 (3.0%) | 4 (1.8%) | NA |
| P17L (PTGS1) | ||||||
| C/C | 524 (89.1%) | 671 (87.9%) | 219 (71.5%) | 159 (72.0%) | ||
| C/T+T/T | 66 (10.9%) | 92 (12.1%) | 0.534c | 90 (28.5%) | 62 (28.0%) | 0.913 |
| G230S (PTGS1) | ||||||
| G/G | 610 (100%) | 773 (100%) | 301 (98.8%) | 215 (98.2%) | ||
| G/A+A/A | 0 (0%) | 0 (0%) | NA | 3 (1.2%) | 4 (1.8%) | NA |
| L237M (PTGS1) | ||||||
| C/C | 563 (93.7%) | 733 (94.0%) | 301 (99.2%) | 220 (99.6%) | ||
| C/A+A/A | 39 (6.3%) | 47 (6.0%) | 0.851 | 3 (0.8%) | 1 (0.4%) | 0.659 |
| G-765C (PTGS2) | ||||||
| G/G | 425 (71.0%) | 546 (70.4%) | 147 (49.7%) | 113 (50.5%) | ||
| G/C+C/C | 182 (29.0%) | 230 (29.6%) | 0.808 | 144 (50.3%) | 111 (49.6%) | 0.873 |
| V511A (PTGS2) | ||||||
| T/T | 591 (100%) | 775 (100%) | 280 (91.9%) | 202 (90.2%) | ||
| T/C+C/C | 0 (0%) | 0 (0%) | NA | 27 (8.1%) | 22 (9.8%) | 0.514 |
CHD, coronary heart disease; NA, not available.
a
Genotype data presented as absolute (percent) genotype frequency. Frequencies are weighted according to the sampling fraction. The R53H variant allele in PTGS1 (rs3842789) was identified in only one African-American non-case.
b
Number of cases and non-cases with available DNA for genotyping (n=131/2,275 did not have DNA available).
c
Distribution of the P17L polymorphism in PTGS1 significantly deviated from Hardy–Weinberg equilibrium in Caucasians (P=0.002).